Replies to post #36125 on Intellipharmaceutics International Inc. (IPCI)

[wimike]

Samsa....makes me worry. What else can they be planning?? I hope not!!!!

[mopar44o]

Might have been a lot of upfront cost associated with launching trials... Only thing I can think off

[doogdilinger]

Hence my recent warnings about people assuming that it's gonna be a direct offering of which Boyd's a part of k Samsa.

IMO only if Boyd had solutions he wouldn't be supporting the reverse split crucifixion in the 1st place.

So although I have no clue what's gonna be done by way of raising the monies Odidi needs to keep the company operating...I don't expect to see a new offering until the R/S gets implemented...and even then I'm definitely not convinced that it's gonna be a direct offering only. In fact I strongly suspect it may be a public offering and could be for up to $15M just to ensure IPCI gets enough cash to get their Oxycontin NDA candidate resubmitted by the end of year and hopefully back in front of another advisory committee panel by next summer.

I can say 1 thing for certain...I definitely don't see Odidi running the company any differently post reverse split than he has pre reverse split...which is why I've been advising caution where Boyd's influence is concerned. Because I'm adamant that if Boyd had solutions for Odidi then he would've brought them to the table and ensured Odidi took positive solution steps without a reverse split.

My fear is that Odidi does a 1 for 15 reverse then does a direct and public offering of which Boyd may or may not be a part of depending on his level of current frustration which imo is just as high as every single 1 of us joe retailers in the way Odidi has managed things to date glta

[AngeloFoca]

I guess after spending 3.5 million a quarter on average I find it strange they are able to get away with only 200k since the middle of July. I would have thought we would have seen one by now.

Either they are not paying the staff, or the rent, or both... or they have had a cash infusion from somewhere... I'm guessing on the latter.

Here's a guess as to where it may have come from... not a probability but at least a possibility from a position of the glass being half-full.

In most cases partnerships have a "minimum performance" clause.

MNK began marketing Seroquel XR in June??? of 2017... which means that by June of 2018 they should/would have sold a yearly minimum "required amount"... if not... IPCI would be owed the difference between what they sold and what they are contractually required to have sold.

It's all guessing... but it may have had a minimum requirement of a million or two $ payable to IPCI on a yearly basis.

Remember that there is an $11 million milestone??? payment payable from MNK to IPCI over the course of the contract... we don't know what the milestones are but it may well be "minimum" yearly royalty payments.